Key facts
- Haichang Biotech’s last known valuation is $383.7M (Dec 2024).
- It has raised $210.7M; the latest was PE Growth/Expansion in Jul 2025.
- Notable investors include Fortune Capital, Huatai Zijin Investment, Heda Ventures, Gang Wang, Dongguan Songshan Lake Science City Venture Capital — 19 tracked in total.
- Status: Privately Held (backing).
Investors
19+- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Haichang Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Haichang Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Haichang Biotech
Developer of nucleic acid therapeutics designed to advance biomedical science and improve human health outcomes. The company offers gene delivery platforms, targeted antitumor modalities, liposomal nanoformulations, and controlled-release drug technologies, enabling pharmaceutical manufacturers, biotechnology enterprises, and biomedical research organizations to enhance therapeutic precision, improve delivery efficiency, and strengthen clinical effectiveness.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2013
- Employees
- 115
- Website
- zjhcbio.com/
- Ownership
- Privately Held (backing)
Haichang Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Haichang Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Haichang Biotech in its N-PORT filings yet. We sweep new filings monthly.